WallStSmart

Ascentage Pharma Group International (AAPG)vsRevolution Medicines Inc (RVMD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Ascentage Pharma Group International generates 86508% more annual revenue ($642.63M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -228.5%. AAPG earns a higher WallStSmart Score of 25/100 (F).

AAPG

Avoid

25

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 3.0
Piotroski: 3/9Altman Z: -2.62

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AAPG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
29.3%8/10

Revenue surging 29.3% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

AAPG4 concerns · Avg: 3.5/10
Price/BookValuation
17.5x4/10

Trading at 17.5x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.41B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
15.7x4/10

Trading at 15.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : AAPG

The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : AAPG

The primary concerns for AAPG are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.76 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

AAPG profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

AAPG is growing revenue faster at 29.3% — sustainability is the question.

AAPG generates stronger free cash flow (-612M), providing more financial flexibility.

Bottom Line

AAPG scores higher overall (25/100 vs 24/100) and 29.3% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ascentage Pharma Group International

HEALTHCARE · BIOTECHNOLOGY · USA

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?